Today's Core ThemeThe tape is telling a valuation story, not a momentum story. With no fresh macro catalyst on the calendar, capital is quietly rotating toward businesses that generate real cash at reasonable prices. The clearest signal: Berkshire Hathaway trades at 13.3x earnings while the growth cohort—Walmart (42.9x), Eli Lilly (42.1x), Broadcom (40.8x), and Palantir (147.6x)—commands multiples three to eleven times higher. In a market where the 10-year yield remains the swing factor, that spread is either an opportunity or a warning, depending on your time horizon. Health scores are uniformly strong (6-8 across the board), which tells us this isn't a quality problem—it's a price problem. The market is paying up for perceived growth durability while discounting steadier compounders. That divergence rarely persists indefinitely without a catalyst, and today's lack of macro news is itself the catalyst: investors are re-underwriting positions on fundamentals alone. Stock Deep-Dive: BRK-BBerkshire Hathaway is the standout on the value side of the ledger. At $532.02 with a 13.27x P/E and a 2.2% FCF yield, the conglomerate offers the widest margin of safety in our coverage universe. A health score of 7 with a BULLISH verdict reflects the structural advantage of a diversified earnings base and a fortress balance sheet—characteristics that matter more when multiples elsewhere look stretched. The 2.2% FCF yield isn't spectacular in isolation, but paired with a 13x multiple it implies a business priced for modest expectations, leaving room for upside surprise. Contrast that with Palantir at 147.6x earnings and a 0.5% FCF yield. PLTR's health score of 8 is well-earned—the business is strong—but the valuation embeds years of flawless execution. Eli Lilly shares the same 0.5% FCF yield at 42x, a reminder that even best-in-class healthcare growth carries duration risk if rates tick higher. Broadcom at 40.8x with a 1.7% FCF yield sits in the middle: quality franchise, premium price, limited cushion. Sector Radar & Key LevelsWatch three things today. First, the rate complex: any uptick in yields pressures the 40x-plus cohort disproportionately, and LLY, AVGO, and PLTR are the most rate-sensitive names in our list. Second, energy: ExxonMobil at 23.0x with a 3.2% FCF yield is the highest cash-return profile here—if crude holds, XOM's NEUTRAL verdict could upgrade on cash-flow strength alone. Third, consumer staples: Walmart at 42.9x and a 1.6% FCF yield is priced for perfection; watch for any volume deceleration that could compress that multiple quickly. Key levels: BRK-B holding above $525 keeps the value bid intact; a break below would signal broader de-risking. PLTR below $180 would test momentum conviction. LLY's $1,250 line is the psychological floor for healthcare growth sentiment. The Investor TakeawayToday's setup rewards discipline over conviction. The 13x-to-147x spread between Berkshire and Palantir is the market's implicit bet on duration—and duration is expensive when rates are uncertain. Balance exposure: own the cash-generative value (BRK-B, XOM) as ballast, and size growth positions (LLY, AVGO, PLTR) to what you can tolerate if multiples compress 20-30%. Health scores are strong across the board; the differentiator is price paid. In a no-news session, valuation is the news.
|